We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: immunotherapy
MedXY News
EnglishTag

immunotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy
newschemoradiotherapydurvalumab

Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy

By MedXY|Dec 10, 2025

The phase III PACIFIC-2 trial found that giving durvalumab from the start of definitive concurrent chemoradiotherapy failed to improve progression-free or overall survival versus placebo; consolidation durvalumab after chemoradiotherapy rem

Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ
Critical CareAnakinraimmunotherapy

Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ

By MedXY|Dec 8, 2025

The ImmunoSep randomized trial found that biomarker-guided immunotherapy (anakinra for macrophage activation‑like syndrome; interferon‑γ for sepsis‑induced immunoparalysis) improved organ dysfunction by day 9 versus placebo, though 28‑day m

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit
newsatezolizumabbevacizumab

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit

By MedXY|Dec 8, 2025

Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results
newshepatocellular carcinomaimmunotherapy

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results

By MedXY|Nov 30, 2025

Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combinati

Pembrolizumab plus Lenvatinib Shows Promising Activity but Substantial Toxicity as Second-Line Therapy After Nivolumab–Ipilimumab in Pleural Mesothelioma
newsimmunotherapylenvatinib

Pembrolizumab plus Lenvatinib Shows Promising Activity but Substantial Toxicity as Second-Line Therapy After Nivolumab–Ipilimumab in Pleural Mesothelioma

By MedXY|Nov 29, 2025

In a single‑arm phase 2 cohort, pembrolizumab plus lenvatinib produced a 60% objective response rate in 20 patients with pleural mesothelioma progressing after first‑line nivolumab plus ipilimumab, but grade 3–4 toxicities were frequent (70

How Cancer Turns Nerves Against Immunity — and a New Strategy That Could Both Relieve Pain and Boost Immunotherapy
Hematology-Oncologyimmunotherapyneuroimmunology

How Cancer Turns Nerves Against Immunity — and a New Strategy That Could Both Relieve Pain and Boost Immunotherapy

By MedXY|Nov 25, 2025

A Cell study shows head and neck cancers hijack a nerve→lymph node circuit (ATF4→SLIT2→sensory neurons→CGRP) to suppress immunity and cause pain — suggesting nerve-targeting drugs could both ease pain and improve immunotherapy.

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity
Hematology-OncologyB-ALLCAR-T

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity

By MedXY|Nov 24, 2025

A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activ

RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical Use
Hematology-Oncologycancer treatmentCRISPR

RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical Use

By MedXY|Nov 14, 2025

RNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.

Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma
newsGastric Cancerimmunotherapy

Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma

By MedXY|Nov 13, 2025

A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric

Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma
newsGastric Cancerimmunotherapy

Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma

By MedXY|Nov 12, 2025

In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophage

Zanzalintinib Plus Atezolizumab Prolongs Survival Versus Regorafenib in Refractory MSS Colorectal Cancer: STELLAR-303 Phase 3 Results
newscolorectal cancerimmunotherapy

Zanzalintinib Plus Atezolizumab Prolongs Survival Versus Regorafenib in Refractory MSS Colorectal Cancer: STELLAR-303 Phase 3 Results

By MedXY|Nov 11, 2025

The phase 3 STELLAR-303 trial shows zanzalintinib plus atezolizumab improves overall survival versus regorafenib in previously treated, microsatellite-stable metastatic colorectal cancer, albeit with higher grade ≥3 toxicity.

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study
newsBCGclinical trial

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study

By MedXY|Nov 11, 2025

One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety

Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights
newsimmunotherapyintrahepatic cholangiocarcinoma

Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights

By MedXY|Nov 7, 2025

Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and s

Outcomes of Maintenance Immunotherapy in Susac Syndrome
NeurologyAutoimmune encephalopathycase report

Outcomes of Maintenance Immunotherapy in Susac Syndrome

By MedXY|Nov 2, 2025

This case series evaluates relapse rates associated with various maintenance immunotherapies in 54 patients with Susac syndrome, highlighting treatment efficacy and challenges in managing this rare autoimmune disorder.

Advances in Gastrointestinal Cancer Therapeutics: Insights from NICHE-2, FOxTROT, Telisotuzumab Adizutecan, and Emerging Trials
GastroenterologyAntibody-drug conjugatecolorectal cancer

Advances in Gastrointestinal Cancer Therapeutics: Insights from NICHE-2, FOxTROT, Telisotuzumab Adizutecan, and Emerging Trials

By MedXY|Oct 30, 2025

This article reviews pivotal updates in gastrointestinal oncology from recent trials, emphasizing superior neoadjuvant immunotherapy in mismatch repair–deficient colorectal cancer, promising antibody-drug conjugates, and challenges in novel

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma
newscamrelizumabEvent-free survival

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma

By MedXY|Oct 30, 2025

In the phase 3 CARES-009 trial, perioperative camrelizumab combined with rivoceranib significantly improved event-free survival and major pathological response in patients with resectable high-risk hepatocellular carcinoma, compared to surg

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study
newsatezolizumabdurvalumab

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study

By MedXY|Oct 29, 2025

A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives
newsBiliary tract cancerchemotherapy

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives

By MedXY|Oct 29, 2025

Immune-checkpoint inhibitors combined with chemotherapy have redefined treatment for advanced biliary tract cancer, offering improved survival despite challenges posed by tumor heterogeneity and biomarker limitations. Ongoing research explo

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study
GastroenterologyBiliary tract cancercisplatin

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

By MedXY|Oct 29, 2025

The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers
newshepatocellular carcinomaimmunotherapy

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers

By MedXY|Oct 28, 2025

Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.

Prev
6 / 9
1…456789
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities